Commonly used reflux and ulcer medication may cause serious kidney damage

April 14, 2016, American Society of Nephrology

New research indicates that long-term use of certain medications commonly used to treat heartburn, acid reflux, and ulcers can have damaging effects on the kidneys. The findings come from a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

In 2013, an estimated 15 million Americans were prescribed (PPIs), which reduce gastric acid production. This number is likely an underestimate because the medications are also available over-the-counter and can be purchased without prescription.

To assess the safety of this widely used drug class, a team led by Yan Xie, MPH and Ziyad Al-Aly, MD, FASN (Clinical Epidemiology Center at the VA Saint Louis Health Care System and Washington University in Saint Louis) analyzed information from the Department of Veterans Affairs national databases. The investigators identified 173,321 new users of PPIs and 20,270 new users of histamine H2 , an alternative class of drugs also used to suppress . Over 5 years of follow-up, those taking PPIs were more likely to experience kidney function decline than those taking H2 receptor blockers. PPI users also had a 28% increased risk of developing chronic kidney disease and a 96% increased risk of developing kidney failure. Furthermore, there was a graded association between duration of PPI use and risk of kidney problems, with those who took PPIs for a longer time being more likely to develop kidney issues.

The findings suggest that long-term use of PPIs may be harmful to the kidneys and should be avoided. PPI use may not only increase the risk of developing chronic kidney disease, but may also increase the risk of its progression to complete failure. "The results emphasize the importance of limiting PPI use only when it is medically necessary, and also limiting the duration of use to the shortest duration possible," said Dr. Al-Aly." A lot of patients start taking PPIs for a medical condition, and they continue much longer than necessary."

The results also provide insights for future investigations on drug safety. "The study serves as a model to leverage the availability of Big Data—with VA data being a prime example—and advanced analytics to determine long term safety profiles of commonly used medications and promote pharmacovigilance," said Xie.

Explore further: Acid reflux medications may increase kidney disease risk

More information: "Proton Pump Inhibitors and Risk of Incident and Progression of Chronic Kidney Disease and ESRD," April 14, 2016, DOI: 10.1681/ASN.2015121377

Related Stories

Acid reflux medications may increase kidney disease risk

October 27, 2015
Certain medications commonly used to treat heartburn and acid reflux may have damaging effects on the kidneys, according to two studies that will be presented at ASN Kidney Week 2015 November 3-8 at the San Diego Convention ...

Proton pump inhibitors associated with risk of chronic kidney disease

January 11, 2016
Proton pump inhibitors (PPIs), which are commonly used drugs to reduce acid in the stomach, appear to be associated with an increased risk of chronic kidney disease but more research is needed to determine whether PPI use ...

Heartburn medicines associated with chronic kidney disease risk

January 18, 2016
A type of heartburn medication called proton pump inhibitors (PPIs) may be linked to long-term kidney damage, according to a new study published in JAMA Internal Medicine.

Proton pump inhibitors may be associated with increased risk of dementia

February 15, 2016
The use of proton pump inhibitors, the popular medications used to treat gastroesophageal reflux and peptic ulcers, may be associated with an increased risk of dementia in a study using data from a large German health insurer, ...

Widely used heartburn and peptic ulcer medicines increase risk of rare kidney disease

March 24, 2014
(Medical Xpress)—New Zealanders taking a proton pump inhibitor (PPI), a type of medicine used to treat gastric acid reflux disorders and peptic ulcer disease, are at an increased risk of a rare kidney disease, according ...

Proton pump inhibitors should be used judiciously to minimize rare adverse events

November 23, 2015
Proton pump inhibitors (PPIs), commonly used for heartburn and gastric distress, should be prescribed at the lowest dose possible and for the shortest length of time because of potential side effects, according to a review ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.